SCHEMBL630715

SCHEMBL630715

Cc1cccc(N2CCN(C(=O)O)CC2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.66
MAPT P10636 3/20 0.66
RAB9A P51151 1/20 0.66
CA12 O43570 1/20 0.60
CA1 P00915 1/20 0.60
CA2 P00918 1/20 0.60
CA9 Q16790 1/20 0.60
NOTUM Q6P988 1/20 0.56
ADRB1 P08588 1/20 0.56
LMNA P02545 3/20 0.55
GAA P10253 2/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
MAPK1 P28482 2/20 0.54
HPGD P15428 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
KCNH2 Q12809 2/20 0.54
USP2 O75604 1/20 0.51
TSHR P16473 1/20 0.51
FFAR4 Q5NUL3 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8230032 0.87 ALDH1A1 (0.61) ALDH1A1MAPTRAB9ACA12CA1
SCHEMBL10501035 0.85 ALDH1A1 (0.60) ALDH1A1MAPTRAB9ACA12CA1
SCHEMBL19710644 0.84 ALDH1A1 (0.72) ALDH1A1MAPTRAB9ALMNAGAA
SCHEMBL11103700 0.84 ADRB1 (0.74) ALDH1A1MAPTRAB9ACA12CA1
SCHEMBL10373770 0.84 ADRB1 (0.74) ALDH1A1MAPTRAB9ACA12CA1
SCHEMBL22054793 0.83 ALDH1A1 (0.57) ALDH1A1MAPTRAB9ACA12CA1
SCHEMBL18997518 0.83 ALDH1A1 (0.57) ALDH1A1MAPTRAB9ACA12CA1
SCHEMBL22054785 0.83 MAPT (0.61) ALDH1A1MAPTRAB9ACA12CA1
SCHEMBL12377877 0.83 TSHR (0.61) ALDH1A1MAPTRAB9ACA12CA1
SCHEMBL5461954 0.83 ALDH1A1 (0.57) ALDH1A1MAPTRAB9ACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2234992-B1 PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2012-02-22 EP claimed
EP-1701946-B1 DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME SANOFI AVENTIS (FR) 2007-12-19 EP claimed
EP-4382521-A1 REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shujing Biopharma Co., Ltd (CN) 2024-06-12 EP disclosed
US-20230121721-A1 MONOACYLGLYCEROL LIPASE INHIBITORS STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) 2023-04-20 US disclosed
WO-2023011608-A1 REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海枢境生物科技有限公司 2023-02-09 WO disclosed
EP-3875452-A1 MONOACYLGLYCEROL LIPASE INHIBITORS Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) 2021-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230121721-A1 MONOACYLGLYCEROL LIPASE INHIBITORS MGLL, PNLIP, LIPA ALDH1A1 932/4885MAPT 2459/4885RAB9A 2641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.